15
Feb
2019

The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

10X Pops on IPO Day, Amgen’s KRAS Drug Tantalizes, & Lilly’s RET Drug Impresses
Vertex’s Bet on T1D, AZ’s Win in T2D CV Outcomes, & FDA Commish Speculation
Amgen Antes Up for Otezla, AbbVie Does the Obvious & an siRNA Nails PCSK9
BIO Leaders Defend Immigrants, Sarepta’s Smackdown, Pfizer Bets $500M on NC